Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. - Wikidata - wikimedia - TriplyDB

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

http://www.wikidata.org/entity/Q34136730

about

Deconstructing innate immune signaling in myelodysplastic syndromes Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Stochastic dynamics and the evolution of mutations in stem cells A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells.Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.Treatment of chronic myeloid leukemia when imatinib fails.In search of CML stem cells' deadly weakness.Stem cell microRNAs in senescence and immortalization: novel players in cancer therapy.Antigens in chronic myeloid leukemia: implications for vaccine development.Immunology and immunotherapy of chronic myeloid leukemia.Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.Novel drug therapies in myeloid leukemia.Interleukin 33 is a guardian of barriers and a local alarmin.Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.Stem cell persistence in chronic myeloid leukemia.Where are we going with CML research?Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations.On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population.Chronic myeloid leukemia: the basis of treatment for tomorrow.Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.

P2860

Q26991974-ECF80DAB-56A3-4340-8DF5-725A019EF603 Q28081844-63F0AF2C-D21C-40C2-B494-D26A0ACEF695 Q31017219-B044B042-08C2-4ECA-AE2A-226DB217B6E9 Q33820371-2F04D0E1-4DBD-4779-85E0-5CD5E4F331C9 Q33834587-90212824-48F0-41F9-AA12-105A6B98B211 Q34154786-E1AFB346-5242-4E25-BEA6-64F1992825D5 Q35016953-449F5105-2B37-4A05-BB3E-3740C651747C Q35044993-6341597D-FC5D-4D45-81A5-D541668572DD Q35634865-4EB973FB-5448-4127-AAA8-070CC4A4AB5D Q35903505-A38D5247-910C-4183-A015-2D3D0116A234 Q35931271-66DB47F0-C04C-4808-BAF2-5524AE824301 Q36008395-847FDB4D-A662-4B05-A707-44BD82969C2A Q36163066-EDB1F75B-B91B-4DCD-B831-0641C9BAF9D2 Q36210636-983CB473-CEFB-4F8C-BDE8-1063CC4944C1 Q36470331-E1DEA18F-58BA-4256-BC52-0F3EB839B187 Q36755221-B176DC1D-A663-42A1-B52D-C17BAF6BFB32 Q36957067-0D98618A-6B51-472F-A954-D0203ACEE8FE Q37487526-1D4551C1-665F-4C35-8920-0FB0C2E98637 Q37702727-F3EEAFA7-44FE-46C4-838C-C4022FFDB1E6 Q37827875-A529E7CC-CB05-43AA-B472-D863133809E1 Q37849628-F3171A1D-6B04-4561-8EA4-FB2D43BA0702 Q37906461-E5471C61-7869-42EC-B70F-5B46AF857DD0 Q37950233-1F2B9CD8-D2D3-4434-9163-E6F7CC6889A9 Q38175864-21B33B19-7F1F-476A-908C-1E40916C071B Q38203882-41EA001C-6064-4E7F-9E44-6E6C85AFDA0D Q38265115-229E9F3C-5796-4D97-B37C-3FFEA066D7A1 Q38510486-199D58C3-CDCD-4CB2-8ED4-3270CCFD4EBF Q38702558-38C65834-F2FB-46CC-B512-D7FEF88C3D3A Q38797633-186B3D2F-5930-40C3-944D-45DCB7AF88F5 Q38812117-77D0EAA1-7528-4C38-AF84-D50F2294AC23 Q38866390-A9816B34-361A-4488-B3E2-0251F6A5ECC2 Q39411920-261FC8F5-DEB1-4CF0-A0ED-0767298FF10D Q39795335-FF626152-BF2D-4C67-A238-2FD81B9C1911 Q40817591-BFC20ACB-D2C4-4EBD-9ED4-5BE5F574F06B Q40817656-6DED7E08-A16F-4DF7-BD10-E0B756898200 Q41610510-DFBEFD54-341F-4E1F-8083-3E7970CA0335 Q41808859-230121DD-A0A7-40A4-A890-0F6D9634BD35 Q42111604-C87983A5-AF36-4D6F-89B1-C759D9852297 Q43004416-E2C5CFF0-B2A3-4314-8BA7-998B4A418D0C Q45340032-BD7FC901-9213-435E-9754-0AA8F8C6D6D7

P2860

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

http://www.wikidata.org/entity/Q34136730

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Isolation and killing of candi ...... -1 receptor accessory protein.

@ast

Isolation and killing of candi ...... -1 receptor accessory protein.

@en

Isolation and killing of candi ...... -1 receptor accessory protein.

@nl

type

label

Isolation and killing of candi ...... -1 receptor accessory protein.

@ast

Isolation and killing of candi ...... -1 receptor accessory protein.

@en

Isolation and killing of candi ...... -1 receptor accessory protein.

@nl

prefLabel

Isolation and killing of candi ...... -1 receptor accessory protein.

@ast

Isolation and killing of candi ...... -1 receptor accessory protein.

@en

Isolation and killing of candi ...... -1 receptor accessory protein.

@nl

P1433

Q34136730-04392775-CB2D-4E2B-90F5-26F630A902A5

P1476

Q34136730-FA065460-B576-4C5F-BDAB-C26DFB970162

P2093

Q34136730-0241DDAA-7696-4004-960E-9B4C4AD65D26

Q34136730-293518D4-C6D0-4D24-80B4-AA183C8EF522

Q34136730-3F8208E5-D003-4813-AE2E-2EF8B8EB31AF

Q34136730-70021CB5-BDF2-4DB9-9FEC-4315836F23C7

Q34136730-87B8C081-18DD-4AF6-A1D9-735928442E4E

Q34136730-A0C78170-3D2D-4836-BD5B-0B54AF70716C

Q34136730-A266E600-5F60-4248-92EA-28FD45D9F37F

Q34136730-BA9536F3-6B96-474A-AA32-0EE5F9079C03

Q34136730-CEEB7819-D35E-4E4E-97D3-27C55FFED321

Q34136730-E26B2153-C1E2-496B-B98D-101F159EFE1C

P2860

Q34136730-025E23FC-2DD4-4788-8B58-3C693F61B016

Q34136730-02F44D20-1A2B-43B0-9E2F-9E90C902EFBB

Q34136730-0FA9E75D-F4B5-4557-9AF5-232ADECEFBC1

Q34136730-149BE687-206F-4C2D-9416-9A5606BE2F5A

Q34136730-1861E0DA-82D4-4AE3-BD1C-F953949B06C6

Q34136730-1F31842D-4CD7-45BC-9C44-37A38E5300D6

Q34136730-2090F54B-2802-4FAE-8F68-7BE49FF0600F

Q34136730-2CE9F41B-4427-461B-B83B-975EEA3E192A

Q34136730-2E27E5F7-BB89-4582-8578-7E04200F1849

Q34136730-53920BD8-FE31-4381-AD3E-AE2357EE8ADD

P304

Q34136730-6349A6EE-998B-4B24-9A21-C67DF0E3FD07

P31

Q34136730-B923CC03-B8C5-4C29-B509-209F29993BC3

P356

Q34136730-55C2E238-BF4E-479E-A46F-57B84D37D11A

P407

Q34136730-B11230F0-B6A6-4B71-ACCA-E488B887FE41

P433

Q34136730-943C905F-EB7C-422A-9241-66A76B64E021

P478

Q34136730-EE7FE717-4BCE-443E-B60B-B9DE56039F52

P50

Q34136730-18066FC0-EC89-4378-B74B-222EDF7E8B1D

P577

Q34136730-79DDC6EB-2748-4936-8FD9-3DADCE05CCA3

P5875

Q34136730-BC72E97B-2E34-4C41-8A97-19CFCF713788

P698

Q34136730-FFC6EC93-7582-41F7-8894-FA00A64BD5E9

P921

Q34136730-6E82CDD6-EF7D-4E1D-A253-6CB5C9E2F4DC

Q34136730-C1AB9B81-E184-4CC2-8F56-8312EAB0593D

Q34136730-DAE0E777-1BFA-421C-A8CB-508D22DE37A5

P932

Q34136730-16419122-2441-4A51-B39A-1712385E8488

P356

PNAS.1004408107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Isolation and killing of candi ...... -1 receptor accessory protein.

@en

P2093

Carin Lassen

http://www.w3.org/2001/XMLSchema#string

Helena Agerstam

http://www.w3.org/2001/XMLSchema#string

Johan Richter

http://www.w3.org/2001/XMLSchema#string

Marcus Järås

http://www.w3.org/2001/XMLSchema#string

Marianne Rissler

http://www.w3.org/2001/XMLSchema#string

Nils Hansen

http://www.w3.org/2001/XMLSchema#string

Panagiotis Tsapogas

http://www.w3.org/2001/XMLSchema#string

Petra Johnels

http://www.w3.org/2001/XMLSchema#string

Thoas Fioretos

http://www.w3.org/2001/XMLSchema#string

Tor Olofsson

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

The interleukin 1 receptor family

Structural organization of the bcr gene and its role in the Ph' translocation

IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

The molecular biology of chronic myeloid leukemia.

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

P304

16280-16285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1004408107

http://www.w3.org/2001/XMLSchema#string

P407

P433

37

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Ole Weis Bjerrum

P577

2010-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46095426

http://www.w3.org/2001/XMLSchema#string

P698

20805474

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

2941341

http://www.w3.org/2001/XMLSchema#string